skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosupressandid - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
ramipril tad tablett
tad pharma gmbh - ramipriil - tablett - 10mg 100tk; 10mg 14tk; 10mg 10tk; 10mg 28tk; 10mg 50tk; 10mg 30tk
ramipril tad tablett
tad pharma gmbh - ramipriil - tablett - 1,25mg 14tk; 1,25mg 90tk; 1,25mg 20tk; 1,25mg 100tk; 1,25mg 30tk; 1,25mg 50tk; 1,25mg 10tk; 1,25mg 60tk
ramipril tad tablett
tad pharma gmbh - ramipriil - tablett - 2,5mg 90tk; 2,5mg 28tk; 2,5mg 20tk; 2,5mg 60tk; 2,5mg 50tk
ramipril tad tablett
tad pharma gmbh - ramipriil - tablett - 5mg 60tk; 5mg 10tk; 5mg 50tk; 5mg 28tk; 5mg 90tk; 5mg 100tk
farydak
pharmaand gmbh - panobinostaadi veevaba laktaat - mitu müeloomit - antineoplastilised ained - farydak kombinatsioonis bortesomiibi ja deksametasooniga, on näidustatud retsidiveerunud refraktoorse hulgimüeloomiga täiskasvanud patsientidele, kes on saanud kaks eelnevat raviskeemi, sealhulgas bortesomiibi ja immunomoduleeriva aine. farydak kombinatsioonis bortesomiibi ja deksametasooniga, on näidustatud retsidiveerunud refraktoorse hulgimüeloomiga täiskasvanud patsientidele, kes on saanud kaks eelnevat raviskeemi, sealhulgas bortesomiibi ja immunomoduleeriva aine.
udenyca
era consulting gmbh - pegfilgrastim - neutropeenia - immunostimulants, , mesilaspere stimuleerivaid faktoreid - neutropeenia ja febriilse neutropeenia esinemissageduse vähendamine ravitud tsütotoksilise kemoteraapia pahaloomulise kasvaja (välja arvatud krooniline müeloidne leukeemia ja müelodüsplastilised sündroomid).
nexium gastroresistentne tablett
grunenthal gmbh - esomeprasool - gastroresistentne tablett - 20mg 7tk; 20mg 140tk; 20mg 28tk; 20mg 14tk
nexium gastroresistentne tablett
grunenthal gmbh - esomeprasool - gastroresistentne tablett - 40mg 28tk; 40mg 14tk
letybo süstelahuse pulber
croma-pharma gmbh - botulismitoksiin - süstelahuse pulber - 50ühik 6tk